Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 108

Similar articles for PubMed (Select 17518125)

1.

The FDA black box for EPO: what should nephrologists do?

Singh AK.

Nephrol News Issues. 2007 May;21(6):55-6, 58-9. No abstract available.

PMID:
17518125
2.

Comment on 'The effect of erythropoietin on the severity of retinopathy of prematurity'.

Modi RR, Padhi TR.

Eye (Lond). 2015 Jan;29(1):149. doi: 10.1038/eye.2014.232. Epub 2014 Oct 3. No abstract available.

PMID:
25277307
3.

Regulatory decision-making: are we getting it right?

Evans SJ, Leufkens HG.

Pharmacoepidemiol Drug Saf. 2014 Oct;23(10):1012-6. doi: 10.1002/pds.3695. Epub 2014 Aug 11. No abstract available.

PMID:
25111962
4.

Anaphylaxis and hypotension after administration of peginesatide.

Bennett CL, Jacob S, Hymes J, Usvyat LA, Maddux FW.

N Engl J Med. 2014 May 22;370(21):2055-6. doi: 10.1056/NEJMc1400883. No abstract available.

5.

Anaphylaxis following the intravenous administration of continuous erythropoietin receptor activator in a haemodialysis patient.

Oh DJ.

Nephrology (Carlton). 2014 May;19(5):304. doi: 10.1111/nep.12213. No abstract available.

PMID:
24750480
6.

Stimulating erythropoiesis in neonates.

Sankaran VG, Agrawal PB.

Am J Hematol. 2013 Nov;88(11):930-1. doi: 10.1002/ajh.23573. Epub 2013 Sep 19. No abstract available.

PMID:
23963872
7.

How do we operationalize the individualization of ESA dosing and target Hb levels?

Finkelstein FO.

Nephrol News Issues. 2013 Jun;27(7):Supp 17-8. No abstract available.

PMID:
23855146
8.

ESA dose vs. Hb levels: what needs to be monitored?

Szczech L.

Nephrol News Issues. 2013 Jun;27(7):Supp 4-5, Supp 22. No abstract available.

PMID:
23855141
9.

How can erythropoeitin-stimulating agent use be reduced in chronic dialysis patients?: Adjuvant therapies to reduce erythropoiesis-stimulating agent dose requirements.

Shah HH, Fishbane SN.

Semin Dial. 2013 Sep-Oct;26(5):543-5. doi: 10.1111/sdi.12108. Epub 2013 Jun 14. Review. No abstract available.

PMID:
23763709
10.

How can erythropoeitin-stimulating agent use be reduced in chronic dialysis patients?: The itsy bitsy anemia problem.

Singh AK.

Semin Dial. 2013 Sep-Oct;26(5):531-4. doi: 10.1111/sdi.12104. Epub 2013 Jun 14. No abstract available.

PMID:
23763643
11.

How can erythropoeitin-stimulating agent use be reduced in chronic dialysis patients?: Can reduction of inflammation improve ESA dose response?

Kovesdy CP.

Semin Dial. 2013 Sep-Oct;26(5):540-2. doi: 10.1111/sdi.12107. Epub 2013 Jun 5. No abstract available.

PMID:
23734775
12.

How can erythropoeitin-stimulating agent use be reduced in chronic dialysis patients?: The "forgotten adjunct therapy": the link between ESA use and control of hyperparathyroidism in chronic kidney disease.

Battistella M, Chan CT.

Semin Dial. 2013 Sep-Oct;26(5):537-40. doi: 10.1111/sdi.12106. Epub 2013 Jun 5. Review. No abstract available.

PMID:
23734745
13.

The normal HCT trial re-revisited: what were the actual findings?

Besarab A, Bolton WK, Nissenson AR, Schwab SJ.

Kidney Int. 2012 Jul;82(2):242; author reply 242-3. doi: 10.1038/ki.2012.204. No abstract available.

PMID:
22743566
14.

A physician's perseverance uncovers problems in a key nephrology study.

Fishbane S, Wish JB.

Kidney Int. 2012 Jul;82(2):135-7. doi: 10.1038/ki.2012.122.

PMID:
22743565
15.

Full results on risks of epoetin emerge 14 years after major dialysis study.

Epstein K.

BMJ. 2012 May 22;344:e3535. doi: 10.1136/bmj.e3535. No abstract available.

PMID:
22619221
16.

Erythropoietin: the swinging pendulum.

Oster HS, Neumann D, Hoffman M, Mittelman M.

Leuk Res. 2012 Aug;36(8):939-44. doi: 10.1016/j.leukres.2012.04.017. Epub 2012 May 11. Review.

PMID:
22579365
17.

The US Food and Drug Administration's Risk Evaluation and Mitigation Strategy (REMS) program in practice: does it really inform patients and limit risk?

Cohen RA, Brown RS.

Am J Kidney Dis. 2012 May;59(5):604-6. doi: 10.1053/j.ajkd.2011.12.008. Epub 2012 Feb 22. No abstract available.

PMID:
22361042
18.

Anemia in the nursing homes: a complex issue.

Morley JE.

J Am Med Dir Assoc. 2012 Mar;13(3):191-4. doi: 10.1016/j.jamda.2011.12.057. Epub 2012 Jan 20. No abstract available.

PMID:
22261540
19.

Dialysis: ESA responsiveness and outcomes in patients on hemodialysis.

Fishbane S, Hazzan A.

Nat Rev Nephrol. 2011 Oct 18;8(1):6-8. doi: 10.1038/nrneph.2011.169. No abstract available.

PMID:
22009249
20.

Hyperhaemolysis syndrome treated with corticosteroids and darbopoietin in a patient with mantle cell lymphoma.

Babb A, Diamantos N, Sekhar M.

Transfus Med. 2012 Apr;22(2):142-4. doi: 10.1111/j.1365-3148.2011.01095.x. Epub 2011 Aug 19. No abstract available.

PMID:
21854471
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk